• Diagnostic Tests

    VisonGate's LuCED test provides early detection of cancer. Sputum is the specimen used for the LuCED test.


    more

  • Patients

    Cell-CT technology provides non-invasive lung cancer screening to aid early diagnosis and provide the best possible outcomes.


    more

  • Healthcare Facilities

    Provide a state-of-the-art detection test to identify lung cancer in the earliest stages, when up to 92% can be cured.


    more



s

Researchers

Medical Device Daily – VisionGate presents at OneMedForum 2012 Conference

Medical Device Daily – VisionGate presents at OneMedForum 2012 Conference

more

VisionGate uses $2.6 million NIH grant to achieve full Automation of Cell-CT™ 3D imaging system for early diagnosis of cancer

VisionGate, Inc., a company developing a revolutionary non-invasive test for the early detection of lung cancer and other applications, today reported that it has achieved full automation of its Cell-CT™ system, a proprietary imaging platform that generates high-resolution 3D biosignatures from intact cells. Development of the fully automated system was funded in part by a [...]

more

VisionGate closes $2 million financing and announces collaboration to evaluate it’s 3D Cell Imaging platform for early lung cancer detection

  VisionGate_Collaborations_Press_Release

more



Copyright 2011 - Visiongate 3d